Vicki Sato Biography and Net Worth

Director of Denali Therapeutics

Vicki Sato, Ph.D., has served as Chairman of our board of directors since December 2016. She was a professor of management practice at Harvard Business School from September 2006 to July 2017 and was a professor in the Department of Molecular and Cell Biology at Harvard University from July 2005 until October 2015. Previously, she served as President of Vertex Pharmaceuticals, Inc., or Vertex, a publicly-traded biotechnology company, which she joined in 1992. Prior to becoming President of Vertex, she was the Chief Scientific Officer and Senior Vice President of Research and Development. Prior to joining Vertex, Dr. Sato served as Vice President of Research at Biogen Inc. Dr. Sato is a member of the board of directors of the following public companies: Akouos, Allogene Therapeutics, and Denali Therapeutics, Inc. Dr. Sato received her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University. She conducted her postdoctoral work at both the University of California, Berkeley and Stanford Medical Center.

What is Vicki L. Sato's net worth?: The estimated net worth of Vicki L. Sato is at least $2.38 million as of November 7th, 2024. Dr. Sato owns 111,056 shares of Denali Therapeutics stock worth more than $2,382,151 as of December 22nd. This net worth estimate does not reflect any other assets that Dr. Sato may own. Learn More about Vicki L. Sato's net worth.
How do I contact Vicki L. Sato?: The corporate mailing address for Dr. Sato and other Denali Therapeutics executives is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. Denali Therapeutics can also be reached via phone at (615) 866-8548 and via email at [email protected]. Learn More on Vicki L. Sato's contact information.
Has Vicki L. Sato been buying or selling shares of Denali Therapeutics?: During the last quarter, Vicki L. Sato has sold $30,600.00 of Denali Therapeutics stock. Most recently, Vicki L. Sato sold 1,020 shares of the business's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $30.00, for a transaction totalling $30,600.00. Following the completion of the sale, the director now directly owns 111,056 shares of the company's stock, valued at $3,331,680. Learn More on Vicki L. Sato's trading history.
Who are Denali Therapeutics' active insiders?: Denali Therapeutics' insider roster includes Jennifer Cook (Director), Carole Ho (Insider), Steve Krognes (CFO), Vicki Sato (Director), David Schenkein (Director), Alexander Schuth (COO), Marc Tessier-Lavigne (Director), and Ryan Watts (CEO). Learn More on Denali Therapeutics' active insiders.
Are insiders buying or selling shares of Denali Therapeutics?: In the last twelve months, insiders at the sold shares 19 times. They sold a total of 274,494 shares worth more than $6,273,411.08. The most recent insider tranaction occured on November, 7th when insider Alexander O Schuth sold 15,558 shares worth more than $465,339.78. Insiders at Denali Therapeutics own 7.9% of the company. Learn More about insider trades at Denali Therapeutics.
Information on this page was last updated on 11/7/2024.

Vicki L. Sato Insider Trading History at Denali Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/7/2024	Sell	1,020	$30.00	$30,600.00	111,056
4/15/2024	Sell	1,666	$18.29	$30,471.14	118,043
2/15/2024	Sell	1,666	$18.37	$30,604.42	121,375
1/16/2024	Sell	1,666	$18.42	$30,687.72	123,041
12/15/2023	Sell	1,666	$23.39	$38,967.74	124,707
11/15/2023	Sell	1,666	$19.13	$31,870.58	126,373
10/16/2023	Sell	1,666	$20.66	$34,419.56	128,039
9/15/2023	Sell	1,666	$23.62	$39,350.92	129,705
8/15/2023	Sell	1,666	$24.30	$40,483.80	131,371
7/17/2023	Sell	1,666	$29.60	$49,313.60	133,037
6/28/2023	Sell	1,666	$29.84	$49,713.44	134,703
11/10/2021	Sell	1,666	$52.81	$87,981.46
9/15/2021	Sell	1,666	$53.40	$88,964.40
8/18/2021	Sell	1,666	$51.70	$86,132.20
7/21/2021	Sell	1,666	$65.13	$108,506.58
6/23/2021	Sell	1,666	$70.74	$117,852.84
5/26/2021	Sell	1,666	$65.37	$108,906.42
4/28/2021	Sell	1,666	$62.15	$103,541.90
3/3/2021	Sell	1,666	$61.61	$102,642.26

Vicki L. Sato Buying and Selling Activity at Denali Therapeutics

Denali Therapeutics Company Overview

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Today's Range

Now: $21.45

$21.00

$22.21

50 Day Range

MA: $25.82

$21.43

$31.58

2 Week Range

Now: $21.45

$14.56

$33.33

Volume

2,810,606 shs

Average Volume

1,062,494 shs

Market Capitalization

$3.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.